Monday, November 16, 2026

Biotech Is Producing Real Data While Capital Tightens: Why Cash Pile and Late-Stage Results Now Matter Most

Phase 3 results, royalty growth and a $3.1B-plus cash balance at Incyte show where biotech value is concrete, while a tech selloff and a funding-target cut signal tighter money. We separate checked SEC figures from company claims and weaker sources.

Via News Editorial Team

November 15, 2026

This article was generated by AI. Built from the source documents listed below. How we work

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Biotech Is Producing Real Data While Capital Tightens: Why Cash Pile and Late-Stage Results Now Matter Most
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Biotech is reporting hard progress in the same fortnight that money for AI and crypto got more expensive to find. Two things have to be read together: what companies can prove clinically and financially, and how much cash they hold while the funding backdrop tightens. This piece leans on SEC-checked numbers where we have them and says plainly where we only have a company's own word.

The backdrop: money got harder to raise

On 30 October 2026 a $1 trillion tech selloff deepened fears of an AI bubble, as big AI bills and weak earnings spooked investors. The Nasdaq 100 had its worst day since June.1 The next day OpenAI cut its funding target by $10 billion.2 On 1 November, Binance users withdrew $3.6 billion when the exchange reopened after a hack.3 For scale, that is roughly the size of Incyte's entire cash balance of $3.46 billion at Q1 2026 (our comparison, using verified figures below).4

Our own reading, which is analysis and not external fact: these events point to a risk-off turn in AI and crypto capital markets. The narrative that Via News's system built from the material suggests the likely winners in biotech are companies with cash runways and late-stage data.5 The rest of this piece tests that idea against what we can verify. We do not have data in the dossier on how biotech share prices reacted, so we make no claim about that.

The strongest checked evidence: Incyte's balance sheet

Incyte is the one company where the dossier holds SEC-sourced, fidelity-checked numbers across several years. Its year-end cash was $3.213 billion in FY 2023, fell to $1.688 billion in FY 2024, then recovered to $3.098 billion in FY 2025.4 The quarterly path is wider still: $987 million at Q2 2024, $1.955 billion at Q2 2025, and $3.982 billion at Q2 2026.4 Q1 2026 stood at $3.461 billion and Q3 2026 at $3.276 billion.4

Two things stand out. First, the cash balance has swung by more than $2 billion within about two years, so a headline cash number is a snapshot, not a promise. The dossier does not say why it fell in 2024 or recovered, and we will not guess. Second, the most recent figure, $3.276 billion, is lower than the $3.982 billion at Q2 2026, a drop of about $0.7 billion in one quarter that readers should watch.4

Cost of revenue, the direct cost of producing what Incyte sells, is rising steadily: $255.0 million in FY 2023, $312.1 million in FY 2024 and $372.1 million in FY 2025.6 Quarterly, it went from $99.0 million in Q3 2025 to $108.7 million in Q3 2026.6 Rising cost of revenue is normal when sales grow, but the dossier holds no revenue figures, so we cannot say whether margins are improving or slipping.

One data oddity we flag rather than hide: capital expenditure is listed at exactly $48.7 million for both FY 2024 and FY 2025.7 Both are marked as checked against SEC filings, but identical figures in consecutive years deserve a second look before anyone builds a model on them. Earnings per share for FY 2023 was $2.65.8

Incyte's pipeline is linked in our records to Jakafi, Opzelura, pemigatinib and a ruxolitinib phosphate cream, and it is based in Wilmington, Delaware. The dossier also records a development programme in PD-1 resistant head and neck cancer. The narrative we started from mentions pancreatic cancer data, but the dossier holds no detail we can verify on it, so we leave it there.

Late-stage data: Vor Bio's two-year Phase 3 result

The clearest clinical result in the material comes from Vor Bio, which reported final two-year results from its Phase 3 TELIGAN trial of telitacicept in IgA nephropathy, a kidney disease. According to the company, kidney function declined by 0.6 mL/min/1.73 m² per year in treated patients against 5.7 for placebo, a difference of 5.1 (p<0.001).9 It also reported 89% and 81% reductions in the risk of confirmed 30% and 40% declines in kidney filtration, with a favourable safety profile.9

These are the company's own statements in a press release, and nothing in the dossier independently confirms them. Press-release sources of this kind held up on 54% of 6,663 claims we checked, which is better than a coin flip but far from reliable enough to treat as settled.9 Late-stage data is what lowers risk for investors; it is also precisely what a company has every reason to present well.

Where revenue is already flowing: BioArctic's royalty

BioArctic offers a cleaner picture of money arriving. Its partner Eisai reported Leqembi sales of JPY 29.3 billion in Q2 2026, which translated into a royalty to BioArctic of SEK 179 million, up about 10 percent on Q2 2025.10 That headline understates the trend. Q2 2025 included a one-time stockpiling effect in China of around JPY 5.3 billion, and the company says that, excluding it, royalty revenues grew approximately 43 percent year on year.10

The important point for a reader weighing funding risk: a royalty is money received without BioArctic carrying the cost of selling the drug. It is the opposite of a company that must keep raising capital to survive. The company's own wording is that the royalty is "an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025."10

Earlier-stage programmes and why runway matters

Scribe Therapeutics reported Q3 2026 results on 12 November, noting it is listed on Nasdaq (SCTX) and raised capital to fund initial clinical development of three programmes. Initial Phase 1 data for STX-1150, its epigenetic silencing therapy for LDL-C lowering, is expected in the first half of 2027.11 Scribe also expanded a collaboration with Sanofi.11 The company argues current LDL-C therapies are limited because "50% to 70% of patients discontinue treatment within one year."11 That is Scribe's claim about the market, not an independent finding. The $174.2 million cash figure in our narrative is not backed by a checked source in the dossier, so we do not rely on it.

Other companies show the same timetable pressure. Ernexa expects an IND filing for ERNA-101 in the third quarter of 2026 and a first-in-human Phase 1 trial in the fourth quarter of 2026.12 Akari expects to start Phase 1 for AKTX-101 in mid-2027.13 For companies a year or more from meaningful data, the question is how long the cash lasts if new funding is hard to find. That is the practical meaning of a tighter backdrop.

The AI-and-biology claims: treat with care

Radical Numerics says AI-designed viruses have treated its first patient, in an experimental treatment targeting drug-resistant E. coli.14 This is a genuine milestone if accurate, but it is the company's statement reported in a newsletter. That publisher's claims held up on only 6% of 16 checked, a sample too small to be conclusive but a clear reason for caution.14

The same publisher carried Generation Lab's claim that its treatment "blocks the systemic spread of aging in the bloodstream, reawakens the body's own repair mechanism and restores health and youth to multiple tissues."15 The article it appears in is headlined as a startup's claim, and the company is the sole source. We include it as an example of the gap between a bold statement and evidence, not as a finding.

What to watch

  • Incyte's cash after the drop from $3.982 billion to $3.276 billion: does it stabilise or keep falling?4
  • Whether Incyte's cost of revenue keeps rising faster than sales, once revenue figures are checked.6
  • Scribe's first Phase 1 data in the first half of 2027.11
  • Ernexa's IND filing due in the third quarter of 2026 and its Phase 1 start in the fourth.12
  • Further moves in the OpenAI funding target and crypto withdrawals, as signs of whether tight money spreads to biotech.2,3

The dossier does not tell us how much of any index fund is exposed to these companies, so we make no claim about whether you already own them.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]News articleMotley Fool
    AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
  2. [2]News articleYahoo Finance· October 15, 2026
    Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
  3. [3]News articleMIT Technology Review
    A startup claims it’s found a drug to make your blood young
  4. [4]News articleYahoo Finance· July 27, 2026
    OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
  5. [5]News articleYahoo Finance· July 29, 2026
    Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
  6. [6]News articleYahoo Finance· November 12, 2026
    Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
  7. [7]News articleYahoo Finance· October 22, 2026
    Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy
  8. [8]News articleMIT Technology Review
    The Download: AI’s trillion-dollar gamble and OpenAI’s biology data bid
  9. [9]News articleMIT Technology Review
    The Download: a secretive antiaging drug and joining virtual power plants
  10. [10]News articleMIT Technology Review
    The Download: computing’s next leap and permafrost’s climate threat
  11. [11]Press releaseGlobeNewswire· July 15, 2026
    Three Biotechs Deliver Catalysts to Watch
  12. [12]News articleNasdaq· July 29, 2026
    Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Built from 12 source documents from 5 publications, dated 15 Jul 2026 to 12 Nov 2026
  2. Published 15 Nov 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.